Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Research & Development (2016 - 2026)

Insight Molecular Diagnostics' Research & Development history spans 6 years, with the latest figure at $5.8 million for Q4 2025.

  • On a quarterly basis, Research & Development rose 158.26% to $5.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $15.9 million, a 61.72% increase, with the full-year FY2025 number at $15.9 million, up 61.6% from a year prior.
  • Research & Development hit $5.8 million in Q4 2025 for Insight Molecular Diagnostics, up from $3.9 million in the prior quarter.
  • Over the last five years, Research & Development for IMDX hit a ceiling of $5.8 million in Q4 2025 and a floor of $1.4 million in Q4 2022.
  • Historically, Research & Development has averaged $2.8 million across 5 years, with a median of $2.5 million in 2021.
  • Biggest five-year swings in Research & Development: tumbled 69.98% in 2022 and later soared 158.26% in 2025.
  • Tracing IMDX's Research & Development over 5 years: stood at $4.6 million in 2021, then tumbled by 69.98% to $1.4 million in 2022, then soared by 84.83% to $2.5 million in 2023, then dropped by 11.39% to $2.3 million in 2024, then surged by 158.26% to $5.8 million in 2025.
  • Business Quant data shows Research & Development for IMDX at $5.8 million in Q4 2025, $3.9 million in Q3 2025, and $3.3 million in Q2 2025.